Olaratumab + Doxorubicin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Soft Tissue Sarcoma
Conditions
Soft Tissue Sarcoma
Trial Timeline
Oct 11, 2016 → Jul 5, 2018
NCT ID
NCT02783599About Olaratumab + Doxorubicin
Olaratumab + Doxorubicin is a phase 1 stage product being developed by Eli Lilly for Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02783599. Target conditions include Soft Tissue Sarcoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02783599 | Phase 1 | Completed |
| NCT02377752 | Phase 1 | Completed |
| NCT02326025 | Phase 1 | Completed |
| NCT01185964 | Phase 1/2 | Completed |
Competing Products
20 competing products in Soft Tissue Sarcoma